Zhitong Hong Kong stocks | People's Bank of China, Ministry of Technology deploy technology financial services in key areas, china life insurance (02628) announces profit joy
China's People's Bank and the Ministry of Technology jointly issued the 'Notice on Improving the Financial Services for Key Technology Areas', guiding and promoting technology financial services in technology-intensive areas such as Beijing, CNI Yangtze Index, and the South China Greater Bay Area concept.
Kintor Pharma Enrols First Patient in Alopecia Drug Trial in China
Kaituo Pharmaceutical-B (09939): The key clinical trial of treating male androgenetic alopecia in adult Chinese men with KX-826 solution 1.0% has completed the first subject enrollment.
Kaituo Pharmaceutical - B (09939) announced that on October 15, 2024, it independently developed and potentially similar...
The tenth batch of national procurement reporting documents have been leaked, industry insiders: does not represent the final list of centralized procurement varieties. The competition intensity will reach new heights.
①A document of the tenth batch of national procurement reporting catalog has circulated within the industry. Today, when the reporter verified with the relevant department, they indicated that it is an internal document not for public release, and the formal joint procurement document will be released publicly later. ②Several industry experts have provided feedback to the reporter, stating that this reporting catalog does not represent the final procurement catalog. However, the competitive landscape of the tenth batch of national procurement will involve at least seven companies. ③The competition for the tenth batch of national procurement will be exceptionally fierce.
Kintor Pharmaceutical Shrinks Loss by 66% in H1; Shares Up 8%
KINTOR PHARMA-B: INTERIM REPORT 2024
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Enter the field of cosmetics, pay attention to the marginal changes and value enhancement behind the expansion of pharmaceutical industry B (9939.HK)
Currently, the innovative drug industry is still experiencing a cold winter moment, and the fundamental relief of the 'water shortage' dilemma has not been achieved. Many companies have to make difficult decisions such as selling pipelines and selling equity. In this stage, how can innovative drug companies break through? Recently, Kaituo Pharmaceuticals released its 2024 mid-year financial report, with a significant reduction of 66.3% in net losses in the first half of the year, and a year-on-year decrease of 76.1% and 33.8% in research and development costs and administrative expenses respectively. At the same time, the company's cash and cash equivalents as well as time deposits are about 34 billion yuan, with ample cash on hand. Through the financial report, it can be seen that as a company that has been deeply cultivating the field of innovative drugs for many years.
Kaituo Pharmaceuticals-B (09939.HK) announced its interim performance with a significant reduction in losses. It is expected to launch seven cosmetics in 2024.
Kaituo Pharmaceutical -B (09939.HK) announced that for the 6 months ended June 30, 2024, the company's net loss decreased by RMB 140.6 million or 66.3% to RMB 71.5 million, compared to RMB 212.1 million in the same period of the previous year. The decrease in this loss was mainly due to a reduction in group research and development costs and administrative expenses.
Kaituo Pharmaceutical-B(09939) released its interim performance. Shareholders had a net loss of 71.493 million yuan, a year-on-year narrowing of 66.29%.
China Grand Pharmaceutical and Healthcare Holdings Limited-B (09939) announced the interim results for the six months ended June 30, 2024, during the period...
Express News | Kintor Pharmaceutical H1 Net Income RMB -71.5 Million
KINTOR PHARMA-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Kaituo Pharmaceutical-B (09939.HK) held a board of directors meeting on August 26 to consider and approve its interim performance.
Kaituo Pharmaceutical-B (09939.HK) announced on August 9 that the board of directors meeting will be held on August 26, 2024 (Monday) to consider and approve the mid-term performance of the company and its subsidiaries ending on June 30, 2024, including its release.
KINTOR PHARMA-B: DATE OF BOARD MEETING
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
No Data
No Data